Kornimate/medical-research-clean huggingface dataset:
cocamide dea vs permethrin for head lice

Conditions: Pediculosis Capitis; Head Louse Infestation

Summary: to assess the efficacy and safety of 10% cocamide dea and lyclear creme rinse (permethrin1%) in the eradication of head lice. to assess the ability of each product to kill all viable ova and to assess patient acceptability of the product in use.

a formulation of cocamide diethanolamine (dea) surfactant was previously reported as showing efficacy to eliminate head louse infestation. this study has been designed to test those data using a new formulation of 10% cocamide dea in an aqueous basis in comparison with the standard of care product 1% permethrin creme rinse. it is believed that surfactants like cocamide dea are capable of eliminating lice resistant to conventional insecticides. a planned total of 120 patients who, following examination, are found to suffer from active head lice infestation will be recruited to the trial. the patient will be treated with the appropriate product according to the randomization code from a pre-prepared listing in balanced blocks of 12. 10% cocamide dea is applied directly to dry hair and is washed off with shampoo after 60 minutes. permethrin 1% creme rinse is applied to shampooed and towel dried hair and left in situ for 10 minutes, then rinsed off with clean water. treatments will be applied by experienced investigators throughout the study. assessments will be made by other investigators unaware of the treatment regimen used. after treatment (day 0), follow up assessments will be performed on days 4, 7,10 then again at day 14 after which they will leave the study. any adverse events or side effects from the treatments will be monitored during the study.

Eligibility criteria:
inclusion criteria: * male and female patients over the age of 4 who are found to have a head lice infection. * patients who give written informed consent or, if the patient is under 16 years of age, whose guardian gives written informed consent to participate in the study. * available for the duration of study i.e. 15 days. exclusion criteria: * patients with a known sensitivity to pyrethroid, organophosphate, and/or carbamate insecticides, sensitivity to chrysanthemums and/or known sensitivity to paraben preservatives. * patients who have been treated with other head lice products within the last 4 weeks. * patients who have undergone a course of antibiotic treatment within the last 4 weeks. * patients who have any persistent skin disorder of the scalp (i.e. eczema, chronic dermatitis, psoriasis). * patients with asthma * patients whose hair has been bleached, colour treated or permed within the last 4 weeks. * pregnant or nursing mothers. * patients who have participated in another clinical trial within 1 month prior to entry to this study. * patients who have already participated in this clinical trial.
effect of moringa oleifera leaf extract on postoperative pain and bacterial reduction in mandibular premolars

Conditions: Necrotic Pulp

Summary: the aim of this study is to clinically compare the intensity of post-operative pain and the amount of bacterial reduction after using moringa oleifera leaf extract solution during chemo-mechanical preparation, versus 2.5% naocl, in asymptomatic necrotic mandibular premolars treated in a single visit


Eligibility criteria:
inclusion criteria: 1. systematically healthy patient (asa i,ii). 2. age between 20 and 55 years 3. male or female. 4. asymptomatic mandibular premolar teeth diagnosed with pulp necrosis with apical periodontitis. 5. radiographic examination using digora intraoral periapical sensor plate and software (digora; soredex, helsinki, finland) showing mandibular premolars with (smaller than 3 mm (0-2 mm)) periapical radiolucency. exclusion criteria: 1. medically compromised patients having significant systemic disorders. (asa iii or iv). 2. history of intolerance to nsaids. 3. teeth with: * immature roots * vital pulp tissues. * association with swelling. * acute peri-apical abscess or acute exacerbation of a chronic abscess. * mobility grade ii or iii. * previously accessed or endodontically treated * deep periodontal pockets more than 4 mm * vertical root fractures, coronal perforation, calcification, and external or internal root resorptions. 4. patients who could not interpret the nrs. 5. patients with diabetes, immune-compromising, and immunosuppression disease and pregnant women were, also, excluded.
single scope staging of lung cancer with endosonography

Conditions: Non Small Cell Lung Cancer (NSCLC); Indication Mediastinal Staging; Complete Endosonography

Summary: rationale: lung cancer is the most commonly diagnosed cancer worldwide and is the most frequent cause of cancer death. accurate staging is important because it directs treatment and prognosis. mediastinal staging can be done by both ebus-tbna and eus-fna. these two techniques have a complementary diagnostic range and the combined procedure is suited for assessment of almost the entire mediastinum. in practice, when mediastinal tissue staging is indicated, endoscopists often perform either an ebus or an eus investigation (instead of the combined procedure). second, frequently only one or two, by imaging suspected lymph node stations, are sampled (ie. targeted approach). objectives: main and secondary: 1. complete endosonographic (combined endobronchial and esophageal) staging using a single ebus scope improves locoregional staging (n2, n3, t4) versus ebus staging alone. 2. systematic mediastinal staging results in improved locoregional staging compared to pet-ct directed assessment of the mediastinum (ie targeted approach). study population: patients with potentially operable and resectable nsclc are eligible if there is an indication for mediastinal nodal sampling. patients have an indication for ebus-tbna. intervention: patients will undergo an ebus investigation followed by eus-b in the same session. during this single scope procedure, lymph nodes that are suspected on prior ct-pet imaging and on subsequent ultrasound are sampled. main study endpoint: the main study parameter is the sensitivity for locoregional disease (n2, n3, t4 disease) of complete endosonographic staging (by ebus-tbna and eus-b-fna) in comparison with ebus staging alone.


Eligibility criteria:
inclusion criteria: * (suspected) nsclc; * indication for mediastinal nodal assessment; * suspected mediastinal lymph nodes within reach of ebus; * age 18 years or older; * clinically fit to undergo surgical resection of the lung tumor; * provision of a written informed consent; exclusion criteria: * mediastinal re-staging after neo-adjuvant treatment; * indication for eus other than mediastinal staging, eg a for malignancy * suspected left adrenal; * active malignancy with a life expectancy of less than two years; * former therapy for lung cancer (chemotherapy, radiotherapy or surgery); * technical contraindication for ebus or eus (eg, esophagus stenosis); * pregnancy; * inability to consent;
older men's decision making about active surveillance for prostate cancer - aim 3: decision aid cognitive and usability testing

Conditions: Prostate Cancer

Summary: this protocol describes development and user testing of an educational shared decision making intervention to help men with prostate cancer who are on active surveillance make decisions with their health care providers about if and when to de-escalate surveillance testing. the project is important because for many patients their cancer does not progress to the point of needed curative treatment or their health status changes such that they are no longer good candidates for treatment. for these men, de-escalating ongoing surveillance (e.g., fewer biopsies or imaging studies) is a reasonable option.

objectives: the overall goal of this protocol is to develop and refine an educational tool for use by patients and health-care providers to help men with localized prostate cancer make informed decisions about discontinuation of active surveillance. * conduct cognitive and initial usability and acceptability testing of a prototype decision aid with patients * conduct cognitive and initial usability and acceptability testing of a prototype decision aid with care partners/caregivers * conduct expert reviews of a prototype decision aid with clinicians

Eligibility criteria:
patients inclusion criteria: 1. males aged 65 or older 2. diagnosis of localized prostate cancer 3. on active surveillance for 12 or more months 4. fluent in english exclusion criteria: 1. receiving treatment for another cancer (primary or recurrence) caregivers inclusion criteria: 1. aged 18 or older 2. fluent in english 3. involved with the care of an eligible patient (i.e. partner, close friend, family member, companion) exclusion criteria: 4. none clinicians inclusion criteria: 1. aged 18 or older 2. fluent in english 3. provides clinical care for patients with prostate cancer (e.g. medical oncologists, urologists, radiation oncologists, nurse practitioners, physician assistants) exclusion criteria: 1. none
in vivo study of interactions between the endocannabinoid system and the corticotropic axis in man

Conditions: Cushing's Syndrome

Summary: working hypothesis: the interactions between the endogenous endocannabinoïds (ecs) - and cortisol, the end product of the hypothalamo-pituitary-adrenal (hpa) axis may play a role in the pathophysiology of cushing's syndrome. the investigators speculate that: * acute or chronic variations in plasma cortisol may induce changes in the activity of the ecs * that there is a circadian rhythm of the ecs driven by the rythm of plasma cortisol

the study aim to identify the relationship between the ecs and the hpa axis in humans with a main objective to assess if cushing's syndrome induces changes in the ecs activity. for this purpose: 1. the investigors will compare plasma levels of ecs between obese controls and patients with cushing's syndrome 2. the investigors will compare plasma levels of ecs in patients with cushing's syndrome before and immediately after curative surgery 3. the investigors will compare plasma levels of ecs in patients with hypoadrenalism before and after the intake of substitutive doses of hydrocortisone 4. the investigors will evaluate the plasma levels of ecs during a short synacthen test in healthy subjects.

Eligibility criteria:
inclusion criteria: for all patients groups: * age ≥ 18, * social security. " hypercortisolism " group: * 18 \< bmi \< 40 kg/m2, * cushing's syndrome in front of : * impaired 1 mg dexamethasone test (08:00 a.m. cortisol \> 50 nmol/l) * qualitative and quantitative disrupted circadian rhythm of cortisol with increased plasma concentrations * free urinary cortisol upper normal range (90 µg/24h), * hypercortisolism that can be treated with surgery (adrenal adenoma treated with adrenalectomy or cushing disease treated with pituitary surgery). " obese " group: * obese patients: 30 \< bmi \< 40 kg/m2, * normal hpa axis function: * 08:00 a.m. cortisol \> 250 nmol/l and peak above 550 nmol/l after 1 mg sst, * normal 24h free urinary cortisol and dexamethasone test. " control " group: * lean or overweight patients (18 \< bmi \< 30 kg/m2), * non cortisol secreting pituitary or adrenal tumor, * patient in whom a biological evaluation of the hpa axis is recommended. " hydrocortisone " group: * lean or overweight patients (18 \< bmi \< 30 kg/m2), * primary or secondary adrenal insufficiency, * with a need for hydrocortisone supplementation. exclusion criteria: * patients with eating disorders, major depressive disorders or psychiatric disorders other than cushing's syndrome, * cannabis consumption, alcoholism or drug addiction, * active smoking, * cortisone treatment other than hydrocortisone, * pregnancy or feeding, * surgery for obesity, * incapability, * pathology that is life-threatening in the short term, * any situation that interfere with study or is risked for patient.

Keywords: obesity cortisol hydrocortisone endocannabinoïds
motion serifos: a study to investigate the efficacy of tradipitant in participants affected by motion sickness

Conditions: Motion Sickness

Summary: a multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel


Eligibility criteria:
inclusion criteria: * history of motion sickness * age 18-75 exclusion criteria: * nausea-inducing disorder other than motion sickness * bmi\>40 * history of intolerance and/or hypersensitivity to neurokinin-1 receptor antagonists
the effect of esketamine on sleep disturbance

Conditions: Sleep Disturbance

Summary: to explore the efficacy of a single low dose of esketamine during surgical abortion in patients with sleep disturbance

sleep disturbance occur in the form of sleep deprivation, circadian rhythm disturbance, and structural abnormalities. women who requires surgical abortion due to fetal anomaly or unwanted pregnancy often experience sleep disturbance. severe sleep disturbance is a strong indicator for postoperative sleep disorders, which can lead to postoperative delirium and cognitive dysfunction, aggravate postoperative pain, and delay postoperative recovery. esketamine is an n-methyl-d-aspartate(nmda) receptor antagonist with analgesic and sedative effects, and is widely used in clinical treatment of refractory depression. for patients undergoing surgical abortion, in addition to sedation and analgesia, whether the intraoperative use of esketamine has positive effects on sleep disturbance is worth exploring.

Eligibility criteria:
inclusion criteria: 1. patients aged 18 years or older with sleep disturbance; 2. american society of anesthesiologists physical status i-iii; 3. a gestational age below 12 weeks; 4. elective surgery is proposed; 5. bmi of 19-30 kg/m2; 6. patients who agreed to enroll in this study voluntarily exclusion criteria: 1. any contraindications to ketamine or esketamine; 2. allergic history of general anesthesia drugs, opioid drugs, non-steroidal drugs; 3. respiratory insufficiency, respiratory failure; 4. bronchial asthma, severe hypertension, severe hepatic and renal dysfunction, severe cardiovascular disease, or hyperthyroidism; 5. bmi\ 30kg/m2; 6. poor compliance, unable to complete the experiment according to the study plan; participants who have participated in clinical trials of other drugs within the last 4 weeks; 7. any circumstances deemed unsuitable for inclusion by the researcher for any reason.

Keywords: esketamine surgical abortion
maternal blood is source to accurately diagnose fetal aneuploidy

Conditions: Pregnant Women; Prenatal Care

Summary: the primary objective of this study is to determine the performance characteristics (sensitivity and specificity) of the verinata health test to detect fetal trisomy 21 (t21) compared to karyotype results obtained by amniocentesis or chorionic villus sampling (cvs). secondary objectives are to assess performance of the test to detect male gender (xy) and other less common aneuploidies (trisomy 13 (t13), trisomy 18 (t18), and turner syndrome (45, x)) compared to clinical fetal karyotype.


Eligibility criteria:
inclusion criteria: * age 18 years or older * clinically confirmed viable pregnancy at the time of enrollment * clinically determined gestational age between 8 wks, 0 days and 22 wks, 0 days * referred or planning to undergo cvs or amniocentesis procedure due to risk of fetal aneuploidy based on protocol-specified clinical indicators * able to provide consent for participation using language appropriate forms and consent process exclusion criteria: - invasive prenatal procedure (amniocentesis or cvs) performed prior to enrollment

Keywords: trisomy 21
a study to compare the safety and effectiveness of indinavir combined with stavudine and lamivudine

Conditions: HIV Infections

Summary: this study will see how safe and effective against hiv the drugs l-756423 plus indinavir (idv) are compared to just idv when taken with stavudine (d4t) and lamivudine (3tc). the study will also see whether taking 1 large dose of l-756423/idv once a day is as safe and effective as taking 2 smaller doses twice a day.

patients are randomized to 1 of 4 treatment arms. in group 1, patients receive a dose of l-756423/idv once daily plus idv placebo. in group 3, patients receive a lower dose of l-756423/idv twice daily (with the daily dosage equaling that of group 1) plus idv placebo. in groups 2 and 4, patients receive equal dosages of idv plus l-756423/idv placebo. in all 4 groups l-756423 and idv are blinded to the investigator and patient. all groups receive open-label d4t and 3tc. patients routinely undergo a physical exam and have blood and urine tests to ensure the drugs' safety and tolerability, which will be evaluated by tabulation of adverse events and clinical assessment of laboratory data. in addition, cd4+ t cell and plasma viral rna levels are measured to quantify the drugs' antiretroviral activity.

Eligibility criteria:
inclusion criteria you may be eligible for this trial if you: * have hiv infection. * have levels of cd4 cells of 100 cells/mm3 or greater. * have a viral load of 10,000 copies/ml or greater. * are 18 years of age or older. exclusion criteria you may not be eligible for this trial if you: * have ever taken anti-hiv drugs.

Keywords: drug therapy, combination drug administration schedule stavudine hiv protease inhibitors lamivudine indinavir reverse transcriptase inhibitors anti-hiv agents
ebus guided cryobiopsies with ultrathin cryoprobe in patients with peripheral pulmonary nodules - a feasibility study

Conditions: Transbronchial Cryobiopsy

Summary: the standard procedure in the diagnosis of peripheral round foci is bronchoscopy with transbronchial forceps biopsy (tbb). despite the simultaneous application of x-ray fluoroscopy, the diagnostic value of this method depends strongly on the size, location and relationship of the foci to the airways as well as their radiological representability. by inserting radial 20 mhz ultrasound probes through the working channel of a flexible bronchoscope into the periphery of the lung, the detection of peripheral foci can be improved. by simultaneously using a virtual bronchoscopy with an ultra-thin bronchoscope, even smaller round foci in the periphery of the lung can be detected. for some years now, tension-resistant cryoprobes have been used for transbronchial biopsy. here, especially in lesions that can only be reached endoscopically tangentially, advantages have been shown over forceps biopsy. much larger tissue samples can be obtained without increasing the complication rate. studies showed that the combination of the ebus navigation technique with the cryobiopsy procedure is feasible and safe in the endoscopic diagnosis of peripheral lung tumors. this study investigates to what extent the combination of an ultra-thin cryoprobe with an ultra-thin bronchoscope together with the radial ebus can further improve the diagnosis. this study is a non-randomized pilot study to prove the feasibility of this procedure. the ebus probe and the bronchoscope are ce certified for this application. the study will be conducted as a monocentric study at the thorax clinic at heidelberg university hospital. a total of 30 patients with an indication for transbronchial biopsy will be prospectively included. all patients will be examined according to the clinical standard. after a freezing time of 3-7 seconds, the probe together with the bronchoscope will be extracted and the sample will be defrosted in a water-filled sample vial. up to 4 biopsies will be taken depending on the investigator's assessment. the samples will be collected separately and the order of the biopsies will be recorded. the primary endpoint is the feasibility of the procedure. secondary endpoints are safety, diagnostic hit rate, biopsy size and quality and success rate depending on the position of the ebus probe (tangential or central).


Eligibility criteria:
inclusion criteria: * single or multiple peripheral pulmonary round foci in ct * signed patient information exclusion criteria: * severe co-mornidity * no signed patien information * contraindication for intervention
clinical presentations before ami onset and coronary atherosclerosis

Conditions: Acute Myocardial Infarction

Summary: this study aimed to evaluate the incidence of preinfarction angina in ami patients and test the hypothesis that different clinical presentations before ami onset can affect coronary plaque morphologies in ami patients .

patients with ami who underwent primary percutaneous coronary intervention（pci） and optical coherence tomography (oct) examination is expected to be included in this study.data about history were prospectively collected by a standard questionaire ,especially regarding the detail information about preinfarction angina.the basic clinical characteristics,angiographic and oct findings are compared between patients with and without preinfarction angina.

Eligibility criteria:
inclusion criteria： 1. men or non-pregnant women \>18 years of age and \< 85 years of age; 2. patients undergo cardiac catheterization for ami; 3. patients able to provide written informed consent. exclusion criteria: 1. patients cant afford medical history; 2. cardiac shock； 3. severe left ventricular dysfunction; 4. left main disease; 5. hepatic or kidney dysfunction; 6. oct was performed after predilation; 7. poor oct image or massive thrombus.
a comparison of ranibizumab and aflibercept for the development of geographic atrophy in (wet) amd patients

Conditions: Age-Related Macular Degeneration

Summary: the purpose of this study was to compare the development of new geographic atrophy in patients with wet age-related macular degeneration (amd) when treated with either ranibizumab or aflibercept over 24 months. geographic atrophy is an advanced form of amd that can result in the progressive and irreversible loss of visual function over time.

in each arm, patients underwent three monthly loading doses (at baseline, week 4, and week 8). from week 8, after the patient had received their third injection of study treatment, the visit intervals were determined by the patient's disease activity. if any of the protocol-specified signs of disease activity were present in the study eye, the subsequent injection visit interval was kept at 4 weeks. if none of the signs were present, the subsequent injection interval was extended by 2-week increments up until a maximum of 12-weekly intervals was reached. if there were any signs of disease activity in the study eye, the treatment interval was reduced as specified in the protocol. the planned individual duration of study participation was 24 months.

Eligibility criteria:
inclusion criteria: - written informed consent. inclusion criteria specific to the study eye: * diagnosis of active subfoveal choroidal neovascularisation (cnv) secondary to wet age-related macular degeneration (amd); * best corrected visual acuity (bcva) score of 23 letters or more as measured by 3-metre early treatment diabetic retinopathy study (etdrs)-like charts. exclusion criteria: * pregnant, nursing, or at risk of becoming pregnant during the study; * inability to comply with the study or follow-up procedures; * recent (3 months) stroke or myocardial infarction; uncontrolled hypertension; hypersensitivity to the study treatments or to fluorescein; * in either eye: active periocular or ocular infection or inflammation; iris neovascularisation; uncontrolled or neovascular glaucoma; or one or more patch of geographic atrophy (ga) as specified in the protocol. exclusion criteria specific to the study eye: * prior or current treatment with anti-angiogenic drugs or corticosteroids; * other eye conditions as specified in the protocol; * any intraocular procedure carried out within 2 months before baseline or anticipated within 6 months following baseline.

Keywords: age-related macular degeneration amd wet amd ranibizumab aflibercept geographic atrophy inject and extend